These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 21545399)

  • 1. Blood pressure effects of naproxcinod in hypertensive patients.
    Townsend R; Bittar N; Rosen J; Smith W; Ramsay A; Chrysant SG; Weiss R; Pivodic A; Duquesroix B; Djian J
    J Clin Hypertens (Greenwich); 2011 May; 13(5):376-84. PubMed ID: 21545399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritis.
    White WB; Schnitzer TJ; Fleming R; Duquesroix B; Beekman M
    Am J Cardiol; 2009 Sep; 104(6):840-5. PubMed ID: 19733721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of naproxcinod in the treatment of patients with osteoarthritis of the knee: a 13-week prospective, randomized, multicenter study.
    Schnitzer TJ; Kivitz A; Frayssinet H; Duquesroix B
    Osteoarthritis Cartilage; 2010 May; 18(5):629-39. PubMed ID: 20202489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of naproxcinod on blood pressure in patients with osteoarthritis.
    White WB; Schnitzer TJ; Bakris GL; Frayssinet H; Duquesroix B; Weber M
    Am J Cardiol; 2011 May; 107(9):1338-45. PubMed ID: 21371681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, safety, and tolerability of the cyclooxygenase-inhibiting nitric oxide donator naproxcinod in treating osteoarthritis of the hip or knee.
    Karlsson J; Pivodic A; Aguirre D; Schnitzer TJ
    J Rheumatol; 2009 Jun; 36(6):1290-7. PubMed ID: 19411388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety, and effects on blood pressure of naproxcinod 750 mg twice daily compared with placebo and naproxen 500 mg twice daily in patients with osteoarthritis of the hip: a randomized, double-blind, parallel-group, multicenter study.
    Baerwald C; Verdecchia P; Duquesroix B; Frayssinet H; Ferreira T
    Arthritis Rheum; 2010 Dec; 62(12):3635-44. PubMed ID: 20722026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naproxcinod, a new cyclooxygenase-inhibiting nitric oxide donator (CINOD).
    Geusens P
    Expert Opin Biol Ther; 2009 May; 9(5):649-57. PubMed ID: 19392579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
    Sowers JR; White WB; Pitt B; Whelton A; Simon LS; Winer N; Kivitz A; van Ingen H; Brabant T; Fort JG;
    Arch Intern Med; 2005 Jan; 165(2):161-8. PubMed ID: 15668361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclooxygenase-inhibiting nitric oxide donators for osteoarthritis.
    Wallace JL; Viappiani S; Bolla M
    Trends Pharmacol Sci; 2009 Mar; 30(3):112-7. PubMed ID: 19230986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naproxcinod shows significant advantages over naproxen in the mdx model of Duchenne Muscular Dystrophy.
    Miglietta D; De Palma C; Sciorati C; Vergani B; Pisa V; Villa A; Ongini E; Clementi E
    Orphanet J Rare Dis; 2015 Aug; 10():101. PubMed ID: 26296873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naproxcinod: AZD 3582, HCT 3012, naproxen nitroxybutylester, nitronaproxen, NO-naproxen.
    Drugs R D; 2007; 8(4):255-8. PubMed ID: 17596112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of naproxcinod in patients with osteoarthritis of the knee: a 53-week prospective randomized multicenter study.
    Schnitzer TJ; Hochberg MC; Marrero CE; Duquesroix B; Frayssinet H; Beekman M
    Semin Arthritis Rheum; 2011 Feb; 40(4):285-97. PubMed ID: 20828790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term treatment with naproxcinod significantly improves skeletal and cardiac disease phenotype in the mdx mouse model of dystrophy.
    Uaesoontrachoon K; Quinn JL; Tatem KS; Van Der Meulen JH; Yu Q; Phadke A; Miller BK; Gordish-Dressman H; Ongini E; Miglietta D; Nagaraju K
    Hum Mol Genet; 2014 Jun; 23(12):3239-49. PubMed ID: 24463621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors.
    White WB; Kent J; Taylor A; Verburg KM; Lefkowith JB; Whelton A
    Hypertension; 2002 Apr; 39(4):929-34. PubMed ID: 11967252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
    Palatini P; Dorigatti F; Mugellini A; Spagnuolo V; Varì N; Ferrara R; Bertocchi F
    Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans.
    Hawkey CJ; Jones JI; Atherton CT; Skelly MM; Bebb JR; Fagerholm U; Jonzon B; Karlsson P; Bjarnason IT
    Gut; 2003 Nov; 52(11):1537-42. PubMed ID: 14570719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake.
    Huledal G; Jonzon B; Malmenäs M; Hedman A; Andersson LI; Odlind B; Brater DC
    Clin Pharmacol Ther; 2005 May; 77(5):437-50. PubMed ID: 15900289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chondroprotective effect of three different classes of anti-inflammatory agents on human osteoarthritic chondrocytes exposed to IL-1β.
    Cheleschi S; Pascarelli NA; Valacchi G; Di Capua A; Biava M; Belmonte G; Giordani A; Sticozzi C; Anzini M; Fioravanti A
    Int Immunopharmacol; 2015 Sep; 28(1):794-801. PubMed ID: 26292179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
    Shimada K; Ogihara T; Saruta T; Kuramoto K;
    Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period.
    White WB; Lacourciere Y; Davidai G
    Am J Hypertens; 2004 Apr; 17(4):347-53. PubMed ID: 15062889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.